Latest news with #ViiVHealthcare
Yahoo
3 days ago
- Health
- Yahoo
Gov. Lamont recognizes Branford lab studying HIV
BRANFORD, Conn. (WTNH) — A pharmaceutical lab and research facility in Branford is being recognized for its efforts to treat, prevent and hopefully cure HIV. ViiV Healthcare is located off exit 54 on I-95. It opened in 2017 and is the world's only HIV-dedicated research facility. New Haven magnet school boasts flourishing drone and robot programs On Monday, Gov. Ned Lamont (D) and the state's health commissioner, Dr. Manisha Juthani, MD, presented the workers there with a proclamation for being a leader in cutting edge research and development in HIV and AIDS. 'It's just worth reminding people every day that we're making a difference and it's working and we're saving lives,' Gov. Lamont said. ViiV is part of an initiative, founded in 2022, that has set a goal to end HIV in the U.S. by 2030. More than 30 scientists work in the Branford facility. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
South Wales Argus
23-05-2025
- Health
- South Wales Argus
Gareth Thomas stepping out of his comfort zone at Chelsea Flower Show.
Created by award-winning designer Manoj Malde, the Tackle HIV Challenging Stigma Garden will be on show at the prestigious event from 20 to 24 May in a bid to challenge harmful stereotypes and showcase the narratives of those living with HIV. Thomas, who leads the Tackle HIV campaign, revealed his pride in the project's beauty and theme after first coming to the flower show two years ago and feeling uncomfortable in the environment due to his HIV status. The Wales rugby icon now hopes that by bringing his and other's stories to life through the garden, he can help educate new audiences on the stigmas surrounding the virus. Created by award-winning designer Manoj Malde, the Tackle HIV Challenging Stigma Garden will be on show at the prestigious event from 20 to 24 May in a bid to challenge harmful stereotypes and showcase the narratives of those living with HIV. (Image: imagecomms) "When I came before, I felt like I was amongst a demographic who potentially didn't have the understanding around HIV, or the only education on it they had had was delivered to them about 40 years ago," he said. "But I felt as a campaigner, going to places and doing things that make you feel uncomfortable are actually the places where you need to be, because that's where you change minds. "This garden is all about celebrating science and medicine, which allows people like me to be able to live normal, happy, healthy lives, not restricted by the virus. "People can come and see that narrative, have that understanding, and that helps break down the stigma engrained in society around HIV." The Tackle HIV Challenging Stigma Garden reflects the significant advancements made in HIV treatment, prevention and care over the last 40 years. From the hexagonal paving that reflects a key chemical structure found within many HIV medications to the words "Undetectable = Untransmittable" etched onto a bench, conveying a crucial educational message about the empowerment provided by effective HIV treatment, each part of the garden tells a crucial part of the story. Created by award-winning designer Manoj Malde, the Tackle HIV Challenging Stigma Garden will be on show at the prestigious event from 20 to 24 May in a bid to challenge harmful stereotypes and showcase the narratives of those living with HIV. (Image: imagecomms) "We have been in the HIV response for the last 40 years, bringing the first medication to market, and transforming the treatment landscape," said Audrey Abernathy, Vice President and Head of External Affairs and Communications at ViiV Healthcare. "But the story that this garden tells is one that hopes to really tackle stigma, because without focusing on tackling stigma as well as medicinal and biopharmaceutical interventions, we're never going to end the epidemic. "Bringing this understanding to new audiences and more unexpected audiences was really important for us to do." In order to bring his vision to life, designer Malde contracted JJH Landscapes to build The Tackle HIV Challenging Stigma Garden. It was an emotional and rewarding project that Justin Himpson was thrilled for his team to be a part of over the past year. "Building a garden at Chelsea is the pinnacle of landscaping and horticulture," he said. "But what this garden is about, and being able to get that across through landscaping and art, has been really inspirational. "It has also been a very emotional build throughout and I think we've delivered something spectacular." The Tackle HIV Challenging Stigma Garden will feature at the Chelsea Flower Show 2025, designed by Manoj Malde and built by JJH Landscapes and Tisserand English Gardens. Tackle HIV is a campaign led by Gareth Thomas in partnership with ViiV Healthcare, with Terrence Higgins Trust as the charity partner, which aims to tackle the stigma and misunderstanding around HIV. For more information visit and follow @tacklehiv.
Wales Online
22-05-2025
- Health
- Wales Online
Rugby legend Gareth Thomas breaks down HIV stigma at the RHS Chelsea Flower Show 2025
Rugby legend Gareth Thomas breaks down HIV stigma at the RHS Chelsea Flower Show 2025 Thomas leads the Tackle HIV campaign and revealed his pride in the Tackle HIV Challenging Stigma Garden's beauty and theme after first coming to the flower show two years ago and feeling uncomfortable in the environment due to his HIV status. Tackle HIV ambassador Gareth Thomas (second from left) at the RHS Chelsea Flower Show (Image: imagecomms ) Rugby legend Gareth Thomas is stepping out of his comfort zone to break down the stigma surrounding HIV at the RHS Chelsea Flower Show 2025. Created by award-winning designer Manoj Malde, the Tackle HIV Challenging Stigma Garden will be on show at the prestigious event from 20 to 24 May in a bid to challenge harmful stereotypes and showcase the narratives of those living with HIV. Thomas, who leads the Tackle HIV campaign, revealed his pride in the project's beauty and theme after first coming to the flower show two years ago and feeling uncomfortable in the environment due to his HIV status. The Wales rugby icon now hopes that by bringing his and other's stories to life through the garden, he can help educate new audiences on the stigmas surrounding the virus. Tackle HIV ambassador Gareth Thomas has 100 caps for Wales (Image: imagecomms ) "When I came before, I felt like I was amongst a demographic who potentially didn't have the understanding around HIV, or the only education on it they had had was delivered to them about 40 years ago," he said. Article continues below "But I felt as a campaigner, going to places and doing things that make you feel uncomfortable are actually the places where you need to be, because that's where you change minds. This garden is all about celebrating science and medicine, which allows people like me to be able to live normal, happy, healthy lives, not restricted by the virus. "People can come and see that narrative, have that understanding, and that helps break down the stigma engrained in society around HIV." The Tackle HIV Challenging Stigma Garden reflects the significant advancements made in HIV treatment, prevention, and care over the last 40 years. From the hexagonal paving that reflects a key chemical structure found within many HIV medications to the words "Undetectable = Untransmittable" etched onto a bench, conveying a crucial educational message about the empowerment provided by effective HIV treatment, each part of the garden tells a crucial part of the story. "We have been in the HIV response for the last 40 years, bringing the first medication to market, and transforming the treatment landscape," said Audrey Abernathy, Vice President and Head of External Affairs and Communications at ViiV Healthcare. Tackle HIV ambassador Gareth Thomas (right), with Amanda Holden (left) at the RHS Chelsea Flower Show (Image: imagecomms ) "But the story that this garden tells is one that hopes to really tackle stigma, because without focusing on tackling stigma as well as medicinal and biopharmaceutical interventions, we're never going to end the epidemic. Bringing this understanding to new audiences and more unexpected audiences was really important for us to do." In order to bring his vision to life, designer Malde contracted JJH Landscapes to build The Tackle HIV Challenging Stigma Garden. It was an emotional and rewarding project that Justin Himpson was thrilled for his team to be a part of over the past year. "Building a garden at Chelsea is the pinnacle of landscaping and horticulture," he said. "But what this garden is about and being able to get that across through landscaping and art, has been really inspirational. It has also been a very emotional build throughout and I think we've delivered something spectacular." Article continues below The Tackle HIV Challenging Stigma Garden will feature at the Chelsea Flower Show 2025, designed by Manoj Malde and built by JJH Landscapes and Tisserand English Gardens. Tackle HIV is a campaign led by Gareth Thomas in partnership with ViiV Healthcare, with Terrence Higgins Trust as the charity partner, which aims to tackle the stigma and misunderstanding around HIV. For more information visit and follow @tacklehiv.
Associated Press
31-03-2025
- Entertainment
- Associated Press
EIGHTH EDITION OF THE RED DRESS BALL SET TO SHINE IN SUPPORT OF PEOPLE LIVING WITH HIV
Join the Party with Purpose — One Night to Change Lives and Challenge HIV Stigma. 'We're not just throwing a party; we're fostering a movement—a dynamic force driving towards a world without HIV stigma while supporting those impacted by HIV.' — Matt Hyams, Director TORONTO, ONTARIO, CANADA, March 31, 2025 / / -- The Red Dress Ball, one of Toronto's most dynamic grassroots fundraisers, returns on Saturday, April 12 at the iconic El Mocambo, calling on the community to raise $100,000 to support people living with HIV. Backed by founding sponsors ViiV Healthcare and DCM, the 2025 edition promises an unforgettable evening of music, performance, and purpose—where every ticket purchased supports frontline services through the Toronto People With AIDS Foundation (PWA Toronto). As Canada marks nearly five decades since the start of the HIV epidemic, the need for stigma-free, community-driven support remains urgent. The Red Dress Ball Foundation, a volunteer-led non-profit, has raised more than $320,000 since its inception to help organizations deliver critical care and resources to people impacted by HIV. 'This isn't just another night out,' says Matt Hyams, Director of The Red Dress Ball Foundation. 'This is about community in action—people coming together in red to support those living with HIV, to challenge stigma, and to fund the programs that make a tangible difference. If you believe in that mission, we ask you to join us.' This year's gala marks the Foundation's eighth anniversary and features an electrifying entertainment lineup. Internationally acclaimed DJ Kitty Glitter (Sydney, Australia) headlines nightly, supported by an all-star roster of drag performers nationwide. New in 2025 is the first official after-party, produced in partnership with MOJO Toronto, which will keep guests dancing into the early hours while pushing the fundraising goal forward. 'As we face rising HIV rates across Canada, grassroots initiatives like The Red Dress Ball play a crucial role in raising awareness and support,' said Raphael Hebert, General Manager of ViiV Healthcare Canada. 'This event fosters solidarity, strengthens connections, and ensures the voices of those affected remain central in the national conversation. We are proud to continue our support.' The 2025 Red Dress Ball offers both VIP and General Admission experiences. Doors open at 7 PM for early access and 8 PM for the main event. The night culminates with the after-party from 11:30 PM to 2:00 AM, creating space for celebration, reflection, and continued giving. Attendees are encouraged to wear red as a symbol of visibility, solidarity, and resistance—anchoring the event's message that no one living with HIV should face stigma or isolation. 'We know that HIV stigma is still a reality for too many,' adds Hyams. 'The Red Dress Ball is a space where we flip that script—where joy, pride, and compassion take centre stage. But we can't do this alone. Every ticket, every donation, and every person in the room helps us move closer to a world where support is the norm, not the exception.' Tickets are available now through Eventbrite, with all proceeds directed to PWA Toronto, a trusted community partner delivering services in housing, mental health, nutrition, and more for those living with HIV. Event Details: ● Date: Saturday, April 12, 2025 ● Time: 7 PM (VIP), 8 PM (General Admission), 1130 PM - 2 AM (After Party) ● Venue: El Mocambo, Toronto --- About The Red Dress Ball Foundation: The Red Dress Ball Foundation is a Canadian non-profit dedicated to raising awareness of the continuing impact of HIV/AIDS in Canada and supporting organizations that assist people living with or at risk of HIV. Through inclusive events rooted in celebration and solidarity, the Foundation builds community, challenges stigma, and drives tangible change. For media inquiries, please contact: Matt Hyams Email: [email protected] Phone: 647-818-3747 Ian Royer Anansi Tales Marketing +1 647-999-8013 email us here YouTube Legal Disclaimer:
Yahoo
17-03-2025
- Business
- Yahoo
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success
ViiV Healthcare is looking to investigate twice-yearly dosing of its human immunodeficiency virus (HIV) therapy, which has been able to suppress viral load in patients dosed every four months in a Phase IIb trial. Results from the company's Embrace trial (NCT05996471) found that 96% of patients dosed with 60mg/kg N6LS (VH109) intravenously (IV), were able to maintain HIV-1 RNA levels below 50 copies per millimetre in blood, compared to 96% in the standard-of-care (SoC) group, who received antiretroviral therapies (ART). At the same time, 88% of another group receiving 3,000mg of N6LS subcutaneously alongside recombinant human hyaluronidase (rHuPH20), were also able to achieve the same effect, maintaining viral load below detectable levels. N6LS was administered in both arms every four months, combined with monthly cabotegravir long-acting injections, in this case using the company's other proprietary HIV regimen, Cabenuva (cabotegravir and rilpivirine). Virologic failure was observed in two patients from each group. Results from the Embrace trial were presented as part of the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, with the company adding that it plans to advance N6LS to six-monthly IV dosing in combination with Cabenuva as part of the Embrace part two study. ViiV Healthcare research and development head Kimberly Smith said: 'The Embrace study demonstrated that VH109, a CD4-binding broadly neutralising antibody, administered every four months with cabotegravir, achieved high efficacy and was well tolerated through six months. 'We're looking forward to continuing the development of VH109 as a component of our future ultra-long-acting regimens.' The London-based company is majority-owned by UK pharmaceutical giant GSK with companies such as Pfizer and Shionogi holding minority shares in the company. The Phase IIb multi-centre, randomised, open-label study recruited 134 patients at 45 locations across the US. The company describes N6LS as a broadly neutralising antibody (bNAbs), a type of antibody that can recognise and block the entry of a broad range of different strains of HIV into healthy cells. The trial secondary endpoint examining the number of AEs found that 64% of the IV group and 65% of the subcutaneous group experienced some form of treatment-related AE. 16% of patients in the subcutaneous group experienced grade 3 and 4 erythema. Infusion site reactions were reported in no IV patients, but 14% of patients in the subcutaneous group. Research by GlobalData's pharmaceutical research centre details that should N6LS make it to market, it is estimated to bring in $41m for ViiV Healthcare, with that figure expected to rise to $247m by the end of 2031. GlobalData is the parent company of Clinical Trials Arena. Elsewhere in the world of HIV therapies, Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for the disease. Meanwhile, massive cutbacks in USAID funding are set to have ramifications on international research in diseases such as HIV. "ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
